Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>N</i>-Acetyl-<i>L</i>-Cysteine as a Potential Adjunctive Strategy in STEC-HUS: Mechanistic Rationale and Current Evidence.

Molecules (Basel, Switzerland)·2026
Same author

Macular degeneration dependent on defense mechanisms conditioned by chemical elements and genetic polymorphism.

Scientific reports·2026
Same author

Gut Microbiome-Hormone Interactions and Precision Fermentation in the Prevention of Early Cardiovascular Risk in Adolescents.

International journal of molecular sciences·2026
Same author

Microplastics as Vectors Influencing Oxidative Stress, Inflammation, and Endocrine Function During Early Development.

International journal of molecular sciences·2026
Same author

Correction: Kurhaluk et al. Role of Antioxidants in Modulating the Microbiota-Gut-Brain Axis and Their Impact on Neurodegenerative Diseases. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 3658.

International journal of molecular sciences·2026
Same author

Astrocytic Redox Homeostasis as a Metabolic Modulator of DNA Damage and Repair in the Ischemic Penumbra.

Cells·2026

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Genetic Polymorphisms and Antioxidant Reactions in Prostate Cancer.

Piotr Kamiński1,2, Joanna Dróżdż-Afelt3, Edward Jacek Gorzelańczyk4,5,6,7

  • 1Division of Ecology and Environmental Protection, Department of Medical Biology and Biochemistry, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, M. Skłodowska-Curie St. 9, PL 85-094 Bydgoszcz, Poland.

International Journal of Molecular Sciences
|May 4, 2026
PubMed
Summary

Environmental factors like pollution and xenobiotics are linked to male reproductive cancers, particularly prostate cancer. Genetic variations and altered antioxidant defenses may increase susceptibility to these environmental stressors.

Keywords:
MDAantioxidant enzymesbiodegradationenvironmental impactgenetic polymorphismsglutathione S-transferasemale reproductive systemoxidative stressprostate cancertrace elements

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.3K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

19.4K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.3K

Area of Science:

  • Environmental Health
  • Reproductive Toxicology
  • Cancer Epidemiology

Background:

  • Environmental factors, including heavy metals and xenobiotics, are known to impact the male reproductive system.
  • Previous studies suggest associations between environmental exposures and prostate cancer, but conclusive evidence is lacking.
  • Understanding defense mechanisms against xenobiotics and their disruption is crucial for cancer research.

Purpose of the Study:

  • To review current literature on environmental factors influencing male reproductive health and cancer development.
  • To analyze the role of xenobiotics and genetic polymorphisms in prostate cancer.
  • To identify research gaps and future directions in environmental carcinogenesis.

Main Methods:

  • Literature review of environmental pollution studies and their effects on the male reproductive system.
  • Analysis of research on xenobiotic defense mechanisms and prostate cancer.
  • Investigation of gene polymorphisms related to stress response and DNA repair.

Main Results:

  • A relationship exists between genetic polymorphisms, antioxidant mechanisms, lipoperoxidation, and trace element levels in men with prostate cancer.
  • Environmental factors and oxidative stress are critical considerations in prostate cancer risk assessment.
  • Individuals with cancer often exhibit disturbed antioxidant enzyme status, potentially impairing defense against carcinogens.

Conclusions:

  • Environmental factors play a significant role in the initiation and progression of male reproductive system cancers, exemplified by prostate cancer.
  • Further population-based studies are needed to elucidate the complex interactions between environmental stressors and cancer incidence.
  • Research into gene-environment interactions and antioxidant defense mechanisms is vital for understanding and preventing male reproductive cancers.